このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Clinical Study of YKYY013 Injection in HBeAg-negative Chronic Hepatitis B Virus-infected Patients Treated With Nucleos(t)Ide Analogues

A Randomized, Double-blind, Multicenter Phase II Clinical Study to Evaluate the Efficacy and Safety of YKYY013 in Patients With HBeAg-negative Chronic Hepatitis B Virus Infection Treated With Nucleos(t)Ide Analogs

To evaluate the efficacy of YKYY013 in patients with chronic hepatitis B virus (HBV) infection with negative hepatitis B e antigen (HBeAg) and treated with nucleoside (acid) analogs (NA).

調査の概要

状態

まだ募集していません

条件

介入・治療

詳細な説明

1)Evaluate the safety and tolerability of YKYY013 in patients with HBeAg-negative chronic HBV infection treated with NA; 2) Evaluate the pharmacokinetic (PK,with the serum drug concentration of YKYY013) and pharmacodynamic (PD,with reduction in HBsAg) characteristics of YKYY013 in patients with HBeAg-negative chronic HBV infection treated with NA; 3) Evaluate the immunogenicity of YKYY013 in patients with HBeAg-negative chronic HBV infection treated with NA.

研究の種類

介入

入学 (推定)

120

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Beijing Municipality
      • Beijing、Beijing Municipality、中国、100050
        • Beijing Friendship Hospital, affiliated with Capital Medical University
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~65年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Body Mass Index (BMI) between 18.0 to 32.0 kg/m^2 (inclusive) and body weight equal to or over 50 kg for male and 45 kg for female.
  2. Chronic HBV infection , with positive hepatitis B surface antigen (HBsAg) or HBV DNA for at least 6 months, and continuous stable treatment with a single nucleoside (acid) analogue (NA) for ≥ 6 months.

3)HBeAg-negative at screening; 4)100 IU/mL < HBsAg ≤ 5000 IU/mL at screening; 5)HBV DNA < 100 IU/mL at screening. 6) Medically approved contraception (e.g., intrauterine device, oral contraceptive, condom) during the trial and for 6 months after the last dose, Participants must not donate sperm or ova during the trial or for 6 months after the last dose.

7) The participants voluntarily participate in the study, and sign the Informed Consent Form (ICF) prior to screening.

Exclusion Criteria:

  1. Severe allergic reactions, non-allergic drug reactions, multiple drug allergies, or known hypersensitivity to the investigational drug or its excipients.

  2. Chronic liver disease other than chronic HBV infection (e.g., severe fatty liver, alcoholic, autoimmune, or inherited metabolic liver disease).

  3. Liver stiffness measurement (LSM) above 9 kPa at screening, or Metavir F3 or higher on biopsy within 1 year before screening.

  4. Current or past hepatic decompensation (e.g., esophagogastric variceal bleeding, ascites, hepatic encephalopathy).

  5. Liver cancer history, or imaging (ultrasound, MRI, CT) suggesting liver cancer, or alpha-fetoprotein (AFP) at least 50 ug/L.

  6. Cardiovascular events (e.g., stroke, transient ischemic attack, myocardial infarction, unstable angina, coronary bypass surgery, percutaneous coronary intervention, heart failure hospitalization) or clinically significant valvular heart disease. Other chronic diseases considered unsuitable by the investigator (e.g., respiratory, endocrine, immune, renal, hepatic, gastrointestinal, dermatologic, hematologic, neurologic).

  7. Active pathological bleeding (e.g., peptic ulcer, intracranial hemorrhage) or bleeding tendency (e.g., recurrent gingival bleeding); cured disease without active or clinically significant bleeding may be enrolled at investigator discretion.

  8. Severe infection within 1 month, or infection symptoms within 7 days, before screening.

  9. Major illness or major surgery (excluding minor outpatient procedures) within 3 months before screening, or planned grade 3-4 surgery during the trial.

  10. Malignancy within 5 years, except cured resected in situ carcinoma (e.g., non-melanoma skin cancer).

  11. Clinically significant abnormalities on physical examination, vital signs, 12-lead electrocardiogram (ECG), or chest CT at screening.

  12. Uncontrolled blood pressure at screening (systolic at least 160 mmHg or diastolic at least 100 mmHg despite treatment).

  13. Fridericia-corrected QT interval (QTcF) at least 450 msec (male) or 470 msec (female); if the first ECG exceeds these limits, two more ECGs are done and the mean of three applies.

  14. Significant laboratory abnormalities at screening, including:

    1. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) at least 2 times the upper limit of normal (ULN).
    2. Total bilirubin at least 2 times ULN with direct bilirubin above ULN.
    3. Serum albumin below 35 g/L.
    4. Platelets below 100 x 10^9/L.
    5. Prothrombin time (PT) prolonged by more than 3 seconds, international normalized ratio (INR) above 1.3, or clinically significant fibrinogen abnormality.
    6. Creatinine clearance (Cockcroft-Gault) 60 mL/min or less, or clinically significant proteinuria.
    7. Poorly controlled diabetes with glycated hemoglobin (HbA1c) above 7.0%.
  15. AIDS, hepatitis A, B, C, or D, or positive screening for HIV antibody, Treponema pallidum antibody, or hepatitis A, B, C, or D antibody; positive hepatitis C antibody requires HCV RNA testing, and positive HCV RNA excludes.

  16. Any potentially hepatotoxic drug (prescription, over-the-counter, or herbal) within 14 days (or 5 half-lives, if longer) before the first dose, if judged unsuitable by the investigator; stable therapy for hypertension or diabetes is allowed.

  17. Interferon or immunosuppressant treatment within 12 months before screening, excluding short-term (2 weeks or less) use and topical or inhaled corticosteroids.

  18. Live vaccine within 1 month before screening.

  19. Small interfering RNA (siRNA) drug trial within 6 months, or other investigational drug within 3 months, before screening; or planned participation in another interventional trial.

  20. Severe intolerance to subcutaneous injection (mild local reactions are acceptable).

  21. Difficult venous access or venipuncture intolerance; history of syncope or hematophobia.

  22. Pregnancy, lactation, or positive pregnancy test at screening or baseline.

  23. Any scientific, compliance, or safety reason for which the investigator considers participation unsuitable.

  24. Inability to communicate or cooperate due to neurologic or psychiatric disorder or language barrier.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:4倍

武器と介入

参加者グループ / アーム
介入・治療
アクティブコンパレータ:YKYY013

Drug: YKYY013 Injection Administration method: Administer subcutaneous injections according to the dose groups A/B/C/D every 4 weeks until the 48th week.

Drug: YKYY013 Injection Administration method: Administer subcutaneous injections according to the dose groups A/B/C/D every 4 weeks until the 48th week.

プラセボコンパレーター:YKYY013 Placebo

Drug: 0.9% Sodium Chloride Injection Administration method: Administer subcutaneous injections according to the dose groups A/B/C/D every 4 weeks until the 48th week.

Drug: 0.9% Sodium Chloride Injection Administration method: Administer subcutaneous injections according to the dose groups A/B/C/D every 4 weeks until the 48th week.

この研究は何を測定していますか?

主要な結果の測定

結果測定
時間枠
The proportion (percent) of participants who achieved serum HBsAg < LLOQ (0.05 IU/mL) and HBVDNA < LLOQ at the 24th week
時間枠:Week 24
Week 24

二次結果の測定

結果測定
時間枠
The proportion (percent) of trial participants who maintained sustained efficacy during the 24-week period after discontinuation of YKYY013 (the NA monotherapy period, up to W72) after completing the YKYY013 treatment course.
時間枠:Week 72
Week 72
The proportion (percent) of participants who achieved serum HBsAg < LLOQ (0.05 IU/mL) and HBV DNA < LLOQ at the end of YKYY013 treatment.
時間枠:Week 48
Week 48
The proportion (percent) of trial participants who met the NA drug discontinuation criteria and stopped all chronic hepatitis B treatments (YKYY013 and NA drugs) and maintained sustained efficacy during a 24-week period.
時間枠:Week 72,Week 96
Week 72,Week 96
The proportion (percent) of trial participants who met the discontinuation criteria for NA treatment at the 72nd week
時間枠:Week 72
Week 72
Compared to the baseline level, the percentage (percent) of participants in the HBsAg test at different levels was reduced (e.g., ≥0.5, ≥1, ≥1.5, ≥2.0, ≥3 log10 IU/mL);
時間枠:From the first day to the 96th week
From the first day to the 96th week
The detection values (IU/mL) of HBsAg;
時間枠:From the first day to the 96th week
From the first day to the 96th week
The maximum reductions (IU/mL) of HBsAg from the baseline;
時間枠:From the first day to the 96th week
From the first day to the 96th week
The relative changes (IU/mL)of HBsAg from the baseline;
時間枠:From the first day to the 96th week
From the first day to the 96th week
The detection values (copies/ml) of HBV RNA;
時間枠:From the first day to the 96th week
From the first day to the 96th week
The maximum reductions (copies/ml) of HBV RNA from the baseline;
時間枠:From the first day to the 96th week
From the first day to the 96th week
The relative changes (copies/ml) of HBV RNA from the baseline;
時間枠:From the first day to the 96th week
From the first day to the 96th week
The detection values (U/mL) of HBcrAg;
時間枠:From the first day to the 96th week
From the first day to the 96th week
The maximum reductions (U/mL) of HBcrAg from the baseline;
時間枠:From the first day to the 96th week
From the first day to the 96th week
The relative changes (U/mL) of HBcrAg from the baseline;
時間枠:From the first day to the 96th week
From the first day to the 96th week
The detection values (IU/mL) of HBV DNA;
時間枠:From the first day to the 96th week
From the first day to the 96th week
The maximum reductions (IU/mL) of HBV DNA from the baseline;
時間枠:From the first day to the 96th week
From the first day to the 96th week
The relative changes (IU/mL) of HBV DNA from the baseline;
時間枠:From the first day to the 96th week
From the first day to the 96th week
The number and percentage (percent) of trial participants whose HBsAg and/or HBV DNA levels have dropped below the quantitative limit;
時間枠:From the first day to the 96th week
From the first day to the 96th week
The number and percentage (percent) of trial participants whose highly sensitive HBsAg (LLOQ ≤ 0.005 IU/mL) decreased below the quantitative limit;
時間枠:From the first day to the 96th week
From the first day to the 96th week
The positive rate (percent) and detection concentration (IU/L) of hepatitis B virus surface antibody (HBsAb);
時間枠:From the first day to the 96th week
From the first day to the 96th week
The positive rate (percent) of hepatitis B virus e antibody (HBeAb).
時間枠:From the first day to the 96th week
From the first day to the 96th week
Adverse events during treatment (TEAE)
時間枠:From the first day to the 96th week
From the first day to the 96th week
Number of participants with abnormally elevated body temperature.
時間枠:From the first day to the 96th week
From the first day to the 96th week
Number of participants with reactions at the injection site from prior administration.
時間枠:From the first day to the 96th week
From the first day to the 96th week
Number of participants with abnormal time between the start of the q wave and the end of the t wave (QT/QTc interval) on 12-lead electrocardiogram (ECG).
時間枠:From the first day to the 96th week
From the first day to the 96th week
Number of participants with liver function abnormalities during the treatment period.
時間枠:From the first day to the 96th week
From the first day to the 96th week
The number and proportion of participants with positive anti-drug antibodies (ADA).
時間枠:Day 1, Day 169, Day 337, Day 505, Day 673, or Early Termination; sampling time windows consistent with visit windows; pre-dose on dosing days
Day 1, Day 169, Day 337, Day 505, Day 673, or Early Termination; sampling time windows consistent with visit windows; pre-dose on dosing days

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年10月30日

一次修了 (推定)

2027年3月20日

研究の完了 (推定)

2029年3月14日

試験登録日

最初に提出

2026年10月21日

QC基準を満たした最初の提出物

2026年11月11日

最初の投稿 (実際)

2026年11月12日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月12日

QC基準を満たした最後の更新が送信されました

2026年11月11日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • CLSP-YKYY013-Z02

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。